Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
All Releases |
|
Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
Apr 8, 2008
|
12.5 KB
|
|
SOUTH SAN FRANCISCO, Calif., April 8, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that a pivotal Phase 3 clinical trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, in patients following total knee replacement surgery, is underway.
In September 2007, An...
|
|
|
Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
Mar 25, 2008
|
13.2 KB
|
|
SOUTH SAN FRANCISCO, CA, March 25, 2008 - Anesiva, Inc. (Nasdaq: ANSV) today announced the initiation of a pivotal Phase 3 trial evaluating Adlea™, its long-acting, non-opioid analgesic drug candidate, in patients following bunionectomy surgery. The multicenter, double-blind, placebo-controlled trial will evaluate the efficacy...
|
|
|
Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Mar 10, 2008
|
11.5 KB
|
|
SOUTH SAN FRANCISCO, Calif., March 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the company has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) to expand the indication for Zingo to treat the pain associated with peripheral IV inser...
|
|
|
Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
Feb 27, 2008
|
8.5 KB
|
|
SOUTH SAN FRANCISCO, Calif., Feb 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that John P. McLaughlin, the company's chief executive officer, will present at the Susquehanna Financial Group SIGnificant Investment Options in Healthcare Conference in New York City on March 5, 2008 at 2:30 pm ...
|
|
|
Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
Feb 11, 2008
|
10.9 KB
|
|
SOUTH SAN FRANCISCO, Calif., Feb 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) and Sigma-Tau SpA have announced an agreement granting an exclusive license to Sigma-Tau for the marketing and distribution of Anesiva's Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system in six E...
|
|
|